Investing.comDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 18:56:30·⟳ 抓取 18:56:58 +28s·⚡ 决策 10-12 18:58:40 +1m42s·14.8 天前
百时美施贵宝admilparant III期IPF试验达主要终点，但高剂量未显效，盘前已涨约5%
这是1200亿美元市值药企的早期管线III期顶线，仅一个低剂量达标、高剂量未达统计显著，方向偏混合；盘前已约+5%（高见63.56、低57.32）且成交量仅约1.3万股，事件在盘前被快速重定价，追高缺乏边际，无近收入、无幅度数据，不具备正期望入场点；亦无可交易的竞争受损方。
📄 原文Investing.com↗ 原文
Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal
By Investing.com Advertisement Advertisement Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal Company Ne…
不做 Bristol-Myers Squibb（BMY.US）
巨型市值药企的偏混合管线III期读出（仅60mg达标、120mg失败、幅度未披露），materiality低；盘前已约+5%且量极薄，消息正被实时定价，追高风险回报不足，也无可交易的竞争受损方。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
BMY的admilparant在IPF III期仅60mg达标、120mg失败，属偏温和且混合的管线利好；对1200亿美元巨头materiality有限，盘前已涨约5%，追高风险回报差，故回避。
消息传播链
- Investing.com基于公司新闻稿报道ALOFT-IPF顶线，60mg达标、120mg未达标；未直接取得BMS IR原始稿件链接，按转述处理市场反应:BMY盘前约+4.96%至62.05美元，区间57.32-63.56，盘前量约1.3万股
- 中文社媒同步简报III期达到主要终点，说明消息已开始跨语言扩散
关键理由
- 60mg达统计学主要终点且安全性良好，降低了该资产完全失败的尾部风险，方向边际正面
- 但相对BMY约1207亿美元市值，单一尚未申报、峰值销售不明的IPF资产短期盈利贡献近乎为零
主要风险
- 120mg未达显著且未披露60mg的FVC改善幅度，临床/商业价值与监管接受度仍存不确定性
- 盘前+5%、量极薄（约1.3万股），正式开盘可能高开低走或回吐，追高易被套
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-12 · 影响 weakens
同一读出中高剂量120mg未达统计学显著，且未披露60mg效应幅度，构成对单边做多的实质削弱；公司仍面临专利悬崖背景
检索:Bristol Myers admilparant phase 3 120mg failed FVC significance IPF competition 原文 ↗
先例如何影响了这次决策
对本次决策的影响:缺乏干净对齐先例叠加盘前已重定价，支持不追高、给AVOID而非设定tp/sl
方向:无可供定量校准的高相似对齐先例
涨幅量级:不足以用先例校准幅度；本次以盘前已实现约+5%作为市场即时定价参考
形态:大型药企单一中早期管线III期读出通常对巨型市值主体仅产生低个位数百分比、且易高开低走的反应，但本次未用真实日线面板验证
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`admilparant lpa1 ipf trial topline results | bmy admilparant idiopathic pulmonary fibrosis 60mg 120mg fvc | bristol myers squibb admilparant aloft-ipf phase 3 primary endpoint`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent que - web_search 成功 doubao_search · 2,978 ms
豆包搜索结果（原始查询:Bristol Myers Squibb admilparant ALOFT-IPF phase 3 topline results press release；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 1,215 ms
{
原文全文
展开原文 · 7,452 字
Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal By Investing.com
Advertisement
Advertisement
Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal
Company News
Published
Oct 12, 2026, 06:56 AM
Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal
View all comments (0)
0
Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal
View all comments (0)
0
© Reuters
In this article:
BMY
-0.77%
PRINCETON, N.J. - Bristol Myers Squibb (
NYSE:BMY
) announced today that its experimental drug admilparant met the primary endpoint in a pivotal Phase 3 trial for idiopathic pulmonary fibrosis, according to a press release statement.
The ALOFT-IPF trial evaluated admilparant at 60 mg and 120 mg doses, administered twice daily for at least 52 weeks, against placebo in approximately 1,255 adults. The 60 mg dose showed a statistically significant improvement in absolute change in forced vital capacity from baseline to Week 52 compared with placebo. The 120 mg dose slowed FVC decline but did not reach statistical significance.
Discontinuations due to adverse events were low and similar to placebo in both admilparant treatment arms. The company described the drug’s safety profile as well-tolerated across both doses.
Admilparant is an orally administered lysophosphatidic acid receptor 1 antagonist. The company characterizes it as a potential first-in-class treatment targeting the LPA1 pathway for pulmonary fibrosis.
Bristol Myers Squibb plans to complete a comprehensive evaluation of the trial data and engage with health authorities for regulatory submissions. Detailed results will be presented at a future medical meeting.
The company is also conducting the Phase 3 ALOFT-PPF trial in progressive pulmonary fibrosis, with topline results expected in early 2027. That trial enrolled approximately 1,057 adults.
Idiopathic pulmonary fibrosis affects approximately 1.4 million people globally. The disease causes irreversible lung tissue damage and scarring, with a median survival time of three to five years following diagnosis and a five-year survival rate of approximately 45%.
Current approved treatments can slow lung function decline, though the company notes limited innovation in the treatment area, with few new therapies approved in more than 10 years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,712.10
+56.9
+0.11%
US 500
7,817.20
+5.7
+0.07%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.49
+0.65
+4.38%
Dollar Index
102.185
+0.163
+0.16%
Crude Oil WTI Futures
92.77
+0.92
+1.00%
Brent Oil Futures
105.73
+1.01
+0.96%
Natural Gas Futures
3.146
-0.074
-2.30%
Gold Futures
4,202.25
-14.05
-0.33%
Silver Futures
60.988
-0.061
-0.10%
Copper Futures
6.7703
+0.0783
+1.17%
US Soybeans Futures
1,283.50
-7.50
-0.58%
U.S. 10Y
5.254
+0.010
+0.19%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.53
-0.06
-0.06%
Euro Bund Futures
121.09
0.00
0.00%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
U.S. futures edge up as Wall St awaits bank earnings and inflation test
By Investing.co
...
Oct 12, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal
Company News
Published
Oct 12, 2026, 06:56 AM
Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal
View all comments (0)
0
Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal
View all comments (0)
0
© Reuters
In this article:
BMY
-0.77%
PRINCETON, N.J. - Bristol Myers Squibb (
NYSE:BMY
) announced today that its experimental drug admilparant met the primary endpoint in a pivotal Phase 3 trial for idiopathic pulmonary fibrosis, according to a press release statement.
The ALOFT-IPF trial evaluated admilparant at 60 mg and 120 mg doses, administered twice daily for at least 52 weeks, against placebo in approximately 1,255 adults. The 60 mg dose showed a statistically significant improvement in absolute change in forced vital capacity from baseline to Week 52 compared with placebo. The 120 mg dose slowed FVC decline but did not reach statistical significance.
Discontinuations due to adverse events were low and similar to placebo in both admilparant treatment arms. The company described the drug’s safety profile as well-tolerated across both doses.
Admilparant is an orally administered lysophosphatidic acid receptor 1 antagonist. The company characterizes it as a potential first-in-class treatment targeting the LPA1 pathway for pulmonary fibrosis.
Bristol Myers Squibb plans to complete a comprehensive evaluation of the trial data and engage with health authorities for regulatory submissions. Detailed results will be presented at a future medical meeting.
The company is also conducting the Phase 3 ALOFT-PPF trial in progressive pulmonary fibrosis, with topline results expected in early 2027. That trial enrolled approximately 1,057 adults.
Idiopathic pulmonary fibrosis affects approximately 1.4 million people globally. The disease causes irreversible lung tissue damage and scarring, with a median survival time of three to five years following diagnosis and a five-year survival rate of approximately 45%.
Current approved treatments can slow lung function decline, though the company notes limited innovation in the treatment area, with few new therapies approved in more than 10 years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,712.10
+56.9
+0.11%
US 500
7,817.20
+5.7
+0.07%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.49
+0.65
+4.38%
Dollar Index
102.185
+0.163
+0.16%
Crude Oil WTI Futures
92.77
+0.92
+1.00%
Brent Oil Futures
105.73
+1.01
+0.96%
Natural Gas Futures
3.146
-0.074
-2.30%
Gold Futures
4,202.25
-14.05
-0.33%
Silver Futures
60.988
-0.061
-0.10%
Copper Futures
6.7703
+0.0783
+1.17%
US Soybeans Futures
1,283.50
-7.50
-0.58%
U.S. 10Y
5.254
+0.010
+0.19%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.53
-0.06
-0.06%
Euro Bund Futures
121.09
0.00
0.00%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
Broadcom CEO says many AI investors are gamblers
By Investing.co
...
Oct 12, 2026
U.S. futures edge up as Wall St awaits bank earnings and inflation test
By Investing.co
...
Oct 12, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
f40c1e96c7· 2026-10-12 18:58 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前